Oppenheimer & CO Inc Intercept Pharmaceuticals, Inc. Transaction History

Oppenheimer & CO Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$46.7 - $92.04 $178,020 - $350,856	-3,812 Closed	0 $0
Q1 2020 May 08, 2020	SELL	$48.35 - $118.68 $231,499 - $568,239	-4,788 Reduced 55.67%	3,812 $240,000
Q4 2019 Feb 07, 2020	SELL	$57.36 - $124.1 $18,011 - $38,967	-314 Reduced 3.52%	8,600 $1.07 Million
Q3 2019 Oct 31, 2019	SELL	$58.69 - $80.46 $41,141 - $56,402	-701 Reduced 7.29%	8,914 $592,000
Q2 2019 Aug 09, 2019	BUY	$77.77 - $120.68 $366,452 - $568,644	4,712 Added 96.1%	9,615 $766,000
Q1 2019 Apr 24, 2019	BUY	$91.83 - $120.68 $231,595 - $304,354	2,522 Added 105.92%	4,903 $548,000
Q4 2018 Jan 29, 2019	SELL	$85.79 - $126.46 $36,460 - $53,745	-425 Reduced 15.15%	2,381 $240,000
Q3 2018 Oct 26, 2018	SELL	$88.49 - $127.55 $323,961 - $466,960	-3,661 Reduced 56.61%	2,806 $355,000
Q2 2018 Aug 10, 2018	SELL	$60.0 - $85.67 $780 - $1,113	-13 Reduced 0.2%	6,467 $542,000
Q1 2018 May 01, 2018	BUY	$52.72 - $67.25 $83,561 - $106,591	1,585 Added 32.38%	6,480 $399,000
Q4 2017 Feb 07, 2018	BUY	$58.2 - $72.76 $6,402 - $8,003	110 Added 2.3%	4,895 $286,000
Q3 2017 Nov 09, 2017	BUY	$57.01 - $118.75 $272,792 - $568,218	4,785	4,785 $278,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.